Glenmark Pharmaceuticals announced its Q1 results for the April–June quarter of financial year 2026, reporting a steep 86% fall in net profit to ₹47 crore compared to the same period last year.

Despite the sharp drop in profitability, the company’s revenue saw a marginal increase, reflecting steady sales performance amid challenging market conditions.

Part of a Busy Earnings Season

The announcement comes during an active earnings season, with nearly 665 companies set to release their April–June quarter results. Alongside Glenmark, other notable names reporting include Vodafone Idea (Vi), Indian Oil Corporation (IOC), Ashok Leyland, AstraZeneca Pharma, Coffee Day Enterprises, Easy Trip Planners, GKB Ophthalmics, Inox Wind, Patanjali Foods, and Sanstar.

Also Read: Proposed H-1B Rule Change Could Alter Indian IT Hiring Landscape

Market Focus on Profitability Pressures

While revenue growth remained slightly positive, the sharp fall in net profit indicates possible cost pressures or lower margins for the company. Investors will be closely watching Glenmark’s upcoming quarters for signs of recovery in profitability.

Click here to explore: Glenmark Pharma

Share This Article

ByRuchika Dave

Follow:

Ruchika Dave is an experienced Intraday Trader and Stock Market Analyst with a strong focus on IPOs, business news, and the Indian economy. As a Marketing Head by profession, she combines strategic expertise with deep market knowledge to deliver accurate and insightful financial analysis trusted by readers and investors alike.